News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galectin Therapeutics Presents At JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop


2/24/2014 8:39:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORCROSS, Ga., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES